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Gadolinium chelate coated gold nanoparticles (Au@DTDTPA) can be applied as
contrast agents for both in vivo X-ray and magnetic resonance imaging. In this
work, our aim was to radiolabel and evaluate this gold nanoparticle with Ga-68, in
order to produce a dual modality PET/MRI imaging probe. For a typical preparation
of 68Ga-labeled nanoparticles, the Au@DTDTPA nanoparticles (Au@DTDTPA/
Au@DTDTPA-RGD) were mixed with ammonium acetate buffer, pH 5 and 40 MBq
of 68Ga eluate. The mixture was then incubated for 45 min at 65 ÅãC. Radiochemi-
cal purity was determined by ITLC. In vitro stability of both radiolabeled species was
assessed in saline and serum. In vitro cell binding experiments were performed on
integrin aνb3 receptor-positive U87MG cancer cells. Non-specific Au@DTDTPA
was used for comparison. Ex vivo biodistribution studies and in vivo PET and MRI
imaging studies in U87MG tumor-bearing SCID mice followed. The Au@DTDTPA
nanoparticles were labeled with Gallium-68 at high radiochemical yield (>95%) and
were stable at RT, and in the presence of serum, for up to 3 h. The cell binding
assay on U87MG glioma cells proved that 68Ga-cRGD-Au@DTDTPA had specific
recognition for these cells. Biodistribution studies in U87MG tumor-bearing SCID
mice showed that the tumor to muscle ratio increased from 1 to 2 h p.i. (3,71 ± 0.22
and 4,69 ± 0.09 respectively), showing a clear differentiation between the affected
and the non-affected tissue. The acquired PET and MRI images were in accordance
to the ex vivo biodistribution results. The preliminary results of this study warrant
the need for further development of Au@DTDTPA nanoparticles radiolabeled with
Ga-68, as possible dual-modality PET/MRI imaging agents.
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